Singapore markets open in 3 hours 52 minutes

Adagene Inc. (ADAG)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
2.6100+0.0200 (+0.77%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5900
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.4400 - 2.7200
52-week range1.1000 - 4.3800
Avg. volume32,604
Market cap115.25M
Beta (5Y monthly)0.52
PE ratio (TTM)N/A
EPS (TTM)-0.4400
Earnings date28 Mar 2024 - 02 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.00
  • GlobeNewswire

    Adagene to Present at Investor Conferences in June

    SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024. Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody® ADG126. Company management will also host investor meetin

  • GlobeNewswire

    Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

    - Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more frequent and repeat dosing of anti-CTLA-4 therapy in combination with anti-PD-1 - - Ongoing combination phase 2 dose expansion in MSS CRC increased to over 50 patients, including initiation of a new, unprecedented 20 mg/kg loading dose regimen, with data anticipated during 2024 -

  • GlobeNewswire

    Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

    - Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”). Dr. Lenz is the Associate Director for Clinica